Patents by Inventor AARON B. NELSON

AARON B. NELSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11911876
    Abstract: A system and method for producing an abrasive article includes a production tool configured to provide shaped abrasive particles to a resin coated backing. A first end and a second end of the production tool are spliced together to form a spliced area. The production tool includes a dispensing surface that includes a plurality of cavities formed between the first end and the second end and configured to receive and hold the shaped abrasive particles. The resin coated backing is configured to receive the shaped abrasive particles from the dispensing surface of the production tool and configured to receive further shaped abrasive particles to fill gaps in the shaped abrasive particles caused by an absence of the plurality of cavities in the spliced area.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: February 27, 2024
    Assignee: 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: Thomas J. Nelson, Aaron K. Nienaber, Joseph B. Eckel, Ann M. Hawkins, Amelia W. Koenig
  • Patent number: 10111889
    Abstract: Absence epilepsy, a form of epilepsy characterized by nonconvulsive seizures, has proven to be refractive to conventional epilepsy therapies. It has been found that low doses of ganaxolone can be used to reduce absence seizures in subjects with absence epilepsy, particularly pediatric subjects. In addition, ganaxolone therapy is particularly useful in subjects with absence epilepsy characterized by a reduction in tonic inhibition. Low dose ganaxolone is also used to reduce sleep disruptions and to treat sleep disorders in subjects in need of such treatment.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: October 30, 2018
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Mathew Victor Jones, Chiara Cirelli, Kile Patrick Mangan, Aaron B. Nelson
  • Publication number: 20170182061
    Abstract: Absence epilepsy, a form of epilepsy characterized by nonconvulsive seizures, has proven to be refractive to conventional epilepsy therapies. It has been found that low doses of ganaxolone can be used to reduce absence seizures in subjects with absence epilepsy, particularly pediatric subjects. In addition, ganaxolone therapy is particularly useful in subjects with absence epilepsy characterized by a reduction in tonic inhibition. Low dose ganaxolone is also used to reduce sleep disruptions and to treat sleep disorders in subjects in need of such treatment.
    Type: Application
    Filed: March 16, 2017
    Publication date: June 29, 2017
    Inventors: MATHEW VICTOR JONES, CHIARA CIRELLI, KILE PATRICK MANGAN, AARON B. NELSON
  • Patent number: 9629853
    Abstract: Absence epilepsy, a form of epilepsy characterized by nonconvulsive seizures, has proven to be refractive to conventional epilepsy therapies. It has been found that low doses of ganaxolone can be used to reduce absence seizures in subjects with absence epilepsy, particularly pediatric subjects. In addition, ganaxolone therapy is particularly useful in subjects with absence epilepsy characterized by a reduction in tonic inhibition. Low dose ganaxolone is also used to reduce sleep disruptions and to treat sleep disorders in subjects in need of such treatment.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: April 25, 2017
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Mathew Victor Jones, Chiara Cirelli, Kile Patrick Mangan, Aaron B. Nelson
  • Publication number: 20150335659
    Abstract: Absence epilepsy, a form of epilepsy characterized by nonconvulsive seizures, has proven to be refractive to conventional epilepsy therapies. It has been found that low doses of ganaxolone can be used to reduce absence seizures in subjects with absence epilepsy, particularly pediatric subjects. In addition, ganaxolone therapy is particularly useful in subjects with absence epilepsy characterized by a reduction in tonic inhibition. Low dose ganaxolone is also used to reduce sleep disruptions and to treat sleep disorders in subjects in need of such treatment.
    Type: Application
    Filed: May 21, 2015
    Publication date: November 26, 2015
    Inventors: MATHEW VICTOR JONES, CHIARA CIRELLI, KILE PATRICK MANGAN, AARON B. NELSON